Pharmacodynamics of echinocandins against Candida glabrata: Requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 10, 2011, Pages 4880-4887

  Howard, Susan J ^a   Livermore, Joanne ^a   Sharp, Andrew ^a   Goodwin, Joanne ^a   Gregson, Lea ^a   Alastruey Izquierdo, A ^b   Perlin, D S ^b   Warn, Peter A ^a   Hope, William W ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN; CASPOFUNGIN; MICAFUNGIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CANDIDA GLABRATA; CANDIDIASIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; FUNGICIDAL ACTIVITY; FUNGUS GROWTH; MALE; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIFUNGAL AGENTS; CANDIDA GLABRATA; CANDIDIASIS; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHINOCANDINS; HUMANS; LIPOPEPTIDES; MALE; MICE; MICROBIAL SENSITIVITY TESTS; NEUTROPENIA;

EID: 80052836823     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00621-11     Document Type: Article

References (34)

1. Abruzzo, G. K., et al. 2000. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob. Agents Chemother. 44:2310-2318.
2. Andes, D., et al. 2010. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob. Agents Chemother. 54:2497-2506.
3. Andes, D., et al. 2008. In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. Antimicrob. Agents Chemother. 52:539-550.
4. Andes, D. R., D. J. Diekema, M. A. Pfaller, K. Marchillo, and J. Bohrmueller. 2008. In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model. Antimicrob. Agents Chemother. 52:3497-3503.
5. Arendrup, M. C., et al. 2011. National surveillance of fungemia in Denmark (2004 to 2009). J. Clin. Microbiol. 49:325-334.
6. Bodey, G. P., et al. 2002. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am. J. Med. 112:380-385.
7. Clinical Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts, 3rd ed., approved standard M27-A3(28). Clinical Laboratory Standards Institute, Wayne, PA.
8. D'Argenio, D. Z., A. Schumitzky, and X. Wang. 2009. ADAPT 5 user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles, CA.
9. Denning, D. W. 2003. Echinocandin antifungal drugs. Lancet 362:1142-1151. (Pubitemid 37222342)
10. Dowell, J. A., et al. 2004. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J. Clin. Pharmacol. 44:590-598.
11. European Committee for Antimicrobial Susceptibility Testing. 2008. EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin. Microbiol. Infect. 14:398-405.
12. Georgopapadakou, N. H. 2001. Update on antifungals targeted to the cell wall: focus on beta-1,3-glucan synthase inhibitors. Expert Opin. Investig. Drugs 10:269-280.
13. Gumbo, T., et al. 2007. Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia. Antimicrob. Agents Chemother. 51:968-974.
14. Gumbo, T., et al. 2006. Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis. Antimicrob. Agents Chemother. 50:3695-3700.
15. Gumbo, T., et al. 2008. Population pharmacokinetics of micafungin in adult patients. Diagn. Microbiol. Infect. Dis. 60:329-331.
16. Hope, W. W., and G. L. Drusano. 2009. Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside. Clin. Microbiol. Infect. 15:602-612.
17. Hope, W. W., et al. 2007. Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis. Antimicrob. Agents Chemother. 51:285-295.
18. Horn, D. L., et al. 2009. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin. Infect. Dis. 48:1695-1703.
19. Howard, S. J., et al. 2011. Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy. J. Infect. Dis. 203:1324-1332.
20. Kuse, E. R., et al. 2007. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369:1519-1527.
21. Leary, R., R. Jelliffe, A. Schumitzky, and M. van Guilder. 2001. An adaptive grid, non-parametric approach to pharmacokinetic and dynamic (PK/PD) models, p. 389-394. In Proceedings of the 14th IEEE Computer Society, Bethesda, MD.
22. Lewis, J. S., Jr., and J. R. Graybill. 2008. Fungicidal versus fungistatic: what's in a word? Expert Opin. Pharmacother. 9:927-935.
23. Mora-Duarte, J., et al. 2002. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347:2020-2029.
24. Pappas, P. G., et al. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
25. Pappas, P. G., et al. 2007. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin. Infect. Dis. 45: 883-893.
26. Park, S., et al. 2005. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob. Agents Chemother. 49:3264-3273.
27. Petraitiene, R., et al. 1999. Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits. Antimicrob. Agents Chemother. 43:2148-2155.
28. Petraitis, V., et al. 2002. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. 46:1857-1869.
29. Sheng, B., M. S. Schwartz, R. B. Desai, A. R. Miller, and B. K. Matuszewski. 2005. A semi-automated procedure for the determination of caspofungin in human plasma using solid-phase extraction and HPLC with fluorescence detection using secondary ionic interactions to obtain a highly purified extract J. Liquid Chromatogr. Related Technol. 28:2895-2908.
30. Slater, J., et al. 2011. Disseminated candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin. Antimicrob. Agents Chemother. 55:3075-3083.
31. Slavin, M. A., et al. 2010. Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death. J. Antimicrob. Chemother. 65:1042-1051.
32. Stone, J. A., et al. 2002. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob. Agents Chemother. 46:739-745.
33. Viscoli, C., et al. 1999. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin. Infect. Dis. 28:1071-1079.
34. Warn, P. A., et al. 2009. Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. Antimicrob. Agents Chemother. 53:3453-3461.